16 April 2021
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received a conversion notice from Mint Capital Advisors Ltd in respect of £950,000 in principal amount of the Convertible Loan Notes issued by the Company on 3 February 2021.
Pursuant to the conversion, the Company will issue, in aggregate, 24,547,803 new ordinary shares of £0.01 each in the capital of the Company (the "New Ordinary Shares") at a conversion price of £0.0387 per Ordinary Share.